Nath Bio-Genes (India) Ltd Share Price Today - Nath Bio-Genes (India) Ltd Stock Price Live NSE/BSE

Nath Bio-Genes (India) Ltd

NSE: NATHBIOGEN BSE: 537291

₹146.78

(-1.81%)

Thu, 12 Mar 2026, 04:09 am

MTF 5xInvest in Nath Bio-Genes (India) Ltd with 5x Leverage Buy with MTF

Market Cap2.82B

PE Ratio6.55

Dividend1.35

Process Industries

Agricultural Commodities/Milling

24.5K

Nath Bio-Genes (India) Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
277.55
Net Profit
38.60
P/B
0.43
Sector P/E
47.98
P/E
7.18
EV/EBITDA
5.65
Debt/Equity (Industry)
0.18
Interest Cover (Industry)
22.10
ROCE (Industry)
16.58
RONW (Industry)
15.21
ROE
6.15
ROCE
6.86
Debt/Equity
0.19
EPS (TTM)
20.49
Dividend Yield
1.37
Book Value
357.74
Interest Cover
4.81

Analysis

all

Pros

Nath Bio-Genes (India) is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Nath Bio-Genes (India) is profitable, therefore cash runway is not a concern.
Nath Bio-Genes (India) is profitable, therefore cash runway is not a concern.
Debt is covered by short term assets, assets are 6.8x debt.
Nath Bio-Genes (India)'s cash and other short term assets cover its long term commitments.

Cons

Unable to evaluate Nath Bio-Genes (India)'s dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Nath Bio-Genes (India)'s dividend against the top 25% market benchmark as the company has not reported any payouts.
Debt is not well covered by operating cash flow (13.6%, less than 20% of total debt).
High level of physical assets or inventory.
Nath Bio-Genes (India) is not covered by any analysts.

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	45.60	45.60	45.60	45.60	45.60
FII	0.31	0.32	0.41	0.21	0.19
DII	0.01	0.76	2.25	3.94	4.37
Public	54.08	53.32	51.75	50.25	49.85
Government	0	0	0	0	0

Technical Analysis

RSI

48.89

MACD

-1.04

50 DMA

148.34

200 DMA

169.85

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	179.93	165.14	157.61	150.35	142.82	135.56	120.77
Fibonacci	165.14	159.49	156.00	150.35	144.70	141.21	135.56
Camarilla	154.14	152.78	151.43	150.35	148.71	147.36	146.00

Pivots Level: Classic

+29.58

179.93

+14.79

165.14

+7.25

157.61

150.35

Pivot Point

LTP: 146.12

-7.54

142.82

-14.79

135.56

-29.58

120.77

Moving Average

SMAEMA

Period

Value

10-EMA
145.68
20-EMA
146.43
30-EMA
147.16
50-EMA
148.90
100-EMA
154.20
200-EMA
162.78

Announcement Date	Purpose	Action	Ex Date
31 Jan 2026	board-meetings	Quarterly Results
13 Nov 2025	board-meetings	Quarterly Results
14 Jul 2025	dividend	Final Dividend - Rs. - 2	14 Aug 2025
29 Apr 2025	agm
29 Apr 2025	dividend	₹2.00 Dividend /Share	14 Aug 2025
12 Jul 2024	agm	Annual General Meeting	13 Aug 2024
09 Jul 2024	dividend	Final Dividend - Rs. - 2	09 Aug 2024
08 May 2024	dividend	₹2.00 Dividend /Share	09 Aug 2024
08 May 2024	agm
07 Feb 2024	egm	Extra- Ordinary General Meeting	08 Mar 2024

Nath Bio-Genes (India) Ltd

Hindustan Unilever Ltd

Varun Beverages Ltd

Godrej Consumer Products Ltd

Nestle India Ltd

Britannia Industries Ltd

Nath Bio-Genes (India) Ltd About

Nath Bio-Genes (India) is engaged in the business of Production, Processing, and Marketing of Hybrid and GM Seeds. The Company has a product range of Field crops, Vegetable crops and Plant Nutrient Supplements.

Industry

Miscellaneous

Founded

1993

Headquarters

CEO

Satish Kagliwal

Employees

Contact

Website

http://www.nathbiogenes.com

investor@nathbiogenes.com; info@nathseeds.com

Phone

91-240-2376314

Location

Nath House Nath Road, P B No 318, Aurangabad., Maharashtra, 431005

Year	History
2000	The company was converted into a Public Limited Company under the name SHIVNATH FARMS LTD.
2001	The company changed its name to Nath Bio-Genes (India) Ltd. The entire business and assets of Seeds Division of Nath Seeds Limited were transferred to Nath Bio-Genes (India) Limited.
2003	The Scheme of Arrangement was approved by the Hon'ble High Court of Bombay.
2014	The company appointed Mrs. Sweta Garodia as a Director.
2020	The company acquired technology from Global Transgenes Limited, an associate company.

Client Name	Order Side	QTY	Avg Price	Date
ADITYA BIRLA SUN LIFE MUTUAL FUND	Sell	126830	165.08	19 Sept 2025
BAKULESH SHAH PRIVATE TRUST	Sell	168000	152.5	05 Mar 2025
BAKULESH TRAMBAKLAL SHAH	Buy	168000	152.5	05 Mar 2025
ADROIT FINANCIAL SERVICES PVT LTD	Buy	133322	261.12	04 Jul 2024
ADROIT FINANCIAL SERVICES PVT LTD	Sell	133322	262.2	04 Jul 2024
JAINAM BROKING LIMITED	Sell	6775	247.38	01 Jul 2024
GRAVITON RESEARCH CAPITAL LLP	Buy	103767	236.35	01 Jul 2024
GRAVITON RESEARCH CAPITAL LLP	Sell	103767	236.15	01 Jul 2024
JAINAM BROKING LIMITED	Buy	111376	245.86	01 Jul 2024
AKASH FARMS LLP	Buy	504000	217	21 Feb 2024

Nath Bio-Genes (India) Ltd News

Tapovan Paper Acquires 0.40% Stake in Nath Bio-Genes

Tapovan Paper and Board Mills Limited acquired 75,645 equity shares (0.40%) in Nath Bio-Genes through a scheme of amalgamation approved by NCLT Mumbai on November 26, 2025.

13 Jan 2026

co actions results

NathBio-Genes Reports 15.9% Revenue Growth to INR 3,199 Million in H1 FY26

NathBio-Genes achieved 15.9% year-on-year revenue growth reaching INR 3,199 million with PAT increasing 15.3% to INR 424 million, driven by strong performance in cotton (26.3% value growth) and vegetable seeds (25% growth). The company maintained steady growth despite erratic monsoons and illegal BT cotton spread, with cotton and paddy contributing 74% of revenue while expanding its product portfolio across maize, vegetable seeds, and plant nutrition solutions.

18 Nov 2025

earnings

NathBio-Genes Reports 23.5% Revenue Growth to Rs 398 Mn in Q2FY26

NathBio-Genes achieved revenue growth of 23.5% to Rs 398 million in quarterly results, driven by strong performance in cotton (6.3% growth to 1.11 million packets) and vegetable seeds (24.4% growth). The company's profit after tax increased 45.4% to Rs 42 million with gross margins expanding to 68% from 60% in the previous year, supported by diversification beyond cotton and growth in high-margin products.

14 Nov 2025

earnings

NATH BIO-GENES Reports Q1 Financial Results

NATH BIO-GENES has reported its Q1 financial results. The company's net profit increased to 382 million rupees from 339 million rupees in the same period last year. Revenue for Q1 rose to 2.8 billion rupees from 2.44 billion rupees year-over-year.

11 Jul 2025

result

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800